NCT00003116View on ClinicalTrials.gov

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 31, 1997

Primary Completion Date

March 31, 2006

Study Completion Date

June 30, 2009

Conditions
LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
BIOLOGICAL

filgrastim

Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.

DRUG

busulfan

high-dose oral busulfan every 6 hours on days -8 to -5

DRUG

cyclophosphamide

cyclophosphamide IV twice a day on days -4 and -3

DRUG

cyclosporine

cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

peripheral blood stem cell transplantation

Allogeneic peripheral blood progenitor cells IV are administered on day 0.

Trial Locations (1)

44106-5065

Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER